Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
NCT ID: NCT00147160
Last Updated: 2012-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
87 participants
INTERVENTIONAL
2003-10-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
NCT00360945
Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
NCT01574092
Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
NCT01887522
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
NCT00180791
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
NCT00404495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Temozolomide, Cisplatinum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours
* Measurable and evaluable disease by the imaging criteria (MRI)
* Patient not previously treated by either of the two drugs
Exclusion Criteria
4 Years
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacques Grill, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Gustave Roussy, Cancer Campus, Grand Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Gustave-Roussy
Villejuif, , France
Bristol Royal Hospital for Children
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSET-2002/978
Identifier Type: -
Identifier Source: secondary_id
CISTEM2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.